Trial NCT03945227

View at ClinicalTrials.gov 
Org. Study IDs: 4-2018-1171

Last trial update was posted on 2020-10-19

MeSH Interventions

Spartalizumab

MeSH Conditions

Carcinoma, Non-Small-Cell Lung

Other Conditions

Stage III NSCLC

Stopping Reasons

Due to the delay in the study shceduled, due to the start of competitive study and the approval of Durvalumab from the Ministry of Food and Drug Safety, it was judged that it was difficult to enroll subjects.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID